Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Tg therapeutics, inc. save search
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -1.36%
H: 2.53%
C: 0.0%
trials therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2022-06-03 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 5.63%
H: 11.62%
C: 6.54%
trials therapeutics presentation sclerosis phase 3 multiple sclerosis
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 0.81%
H: 5.31%
C: 1.2%
trials therapeutics sclerosis phase 3 multiple sclerosis
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
Published: 2022-04-06 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -2.1%
H: 3.71%
C: 2.34%
trials therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
Published: 2022-04-04 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 0.4%
H: 5.43%
C: 5.34%
trials therapeutics sclerosis phase 3 multiple sclerosis
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
Published: 2022-03-04 (Crawled : 13:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -11.07%
H: 0.0%
C: 0.0%
america multiple sclerosis als trials trial therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2022-02-25 (Crawled : 13:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 10.03%
H: 0.0%
C: 0.0%
america multiple sclerosis treatment als trials research trial therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2022-02-15 (Crawled : 13:30) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 2.51%
H: 8.21%
C: 6.84%
america multiple sclerosis treatment als trials research trial therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -5.49%
H: 2.43%
C: -2.68%
ema trial therapeutics phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Published: 2021-09-29 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 0.7%
H: 2.16%
C: 0.9%
presentation multiple sclerosis treatment europe trials sclerosis phase 3 research trial
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
Published: 2021-06-18 (Crawled : 19:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
| Email alert
Add to watchlist
presentation multiple sclerosis europe sclerosis phase 3 trial
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -0.24%
H: 0.63%
C: -0.29%
europe phase 1 therapy phase 3
TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and VenetoclaxULTRA-V Phase 2 trial has reached completion of patient enrollment
Published: 2021-04-21 (Crawled : 12:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -2.41%
H: 4.86%
C: 4.42%
phase 2 phase 3 trial enroll
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
Published: 2021-04-16 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 4.52%
H: 3.11%
C: -6.51%
multiple sclerosis positive results positive results sclerosis phase 3 trial
TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple SclerosisWebcast to be held tomorrow, April 16, 2021 at 8:30 AM ET
Published: 2021-04-15 (Crawled : 23:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 1.3%
H: 1.88%
C: 1.51%
multiple sclerosis results sclerosis phase 3 trial
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting
Published: 2021-03-04 (Crawled : 00:05) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 0.7%
H: 3.41%
C: 3.29%
multiple sclerosis results sclerosis phase 3 trial
TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology
Published: 2021-02-23 (Crawled : 13:01) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -2.81%
H: 5.14%
C: 2.69%
risk results leukemia phase 3 trial lancet
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 11.75%
H: 29.43%
C: 26.04%
positive therapy multiple sclerosis results sclerosis phase 3 treatment topline
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
WLGS | $0.59 18.0% 17.9% 2.3M
|
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
MGOL 4 | $0.229 -4.18% 13.72% 420K
|
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
BQ | $0.269 1.51% 11.15% 1.1M
|
Consumer Non-Durables
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.